Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $115.3 million.

  • Amicus Therapeutics' Operating Expenses rose 820.61% to $115.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $504.7 million, marking a year-over-year increase of 1495.24%. This contributed to the annual value of $450.5 million for FY2024, which is 255.78% up from last year.
  • As of Q3 2025, Amicus Therapeutics' Operating Expenses stood at $115.3 million, which was up 820.61% from $148.9 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Operating Expenses ranged from a high of $148.9 million in Q2 2025 and a low of $100.4 million during Q2 2024
  • In the last 5 years, Amicus Therapeutics' Operating Expenses had a median value of $115.3 million in 2025 and averaged $118.7 million.
  • In the last 5 years, Amicus Therapeutics' Operating Expenses tumbled by 2170.38% in 2023 and then surged by 4829.1% in 2025.
  • Amicus Therapeutics' Operating Expenses (Quarter) stood at $146.4 million in 2021, then fell by 17.35% to $121.0 million in 2022, then fell by 11.23% to $107.4 million in 2023, then rose by 10.66% to $118.9 million in 2024, then fell by 3.01% to $115.3 million in 2025.
  • Its Operating Expenses stands at $115.3 million for Q3 2025, versus $148.9 million for Q2 2025 and $121.5 million for Q1 2025.